Thrombolytic Therapy for Acute Pulmonary Embolism

被引:23
|
作者
Tapson, Victor F. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Ctr Pulm Vasc Dis, Durham, NC 27710 USA
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2013年 / 39卷 / 04期
关键词
pulmonary embolism; deep venous thrombosis; thrombolytic therapy; right ventricular function; catheter-based embolectomy; ANGIOJET RHEOLYTIC THROMBECTOMY; HEMODYNAMICALLY STABLE PATIENTS; CONTROLLED CLINICAL-TRIAL; DEEP-VEIN THROMBOSIS; TROPONIN-T ASSAY; PLASMINOGEN-ACTIVATOR; NORMOTENSIVE PATIENTS; SURGICAL EMBOLECTOMY; RANDOMIZED-TRIAL; SEVERITY INDEX;
D O I
10.1055/s-0033-1334145
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombolytic therapy accelerates the dissolution of acute pulmonary embolism and is potentially lifesaving. The goal of this article is to offer a critical analysis of the use of thrombolytic therapy in this setting. Guidelines have been written and modified and new ones have been published over the past several years. Although an evidence base exists, unanswered questions remain. Despite the potential benefit of rapid clot lysis, nonpathologic thrombi are also lysed, so that thrombolytic therapy can cause significant bleeding complications. Massive acute pulmonary embolism is the clearest indication for these drugs, and although thrombolysis has been studied in submassive pulmonary embolism, this scenario remains more controversial. Traditionally, thrombolytic agents have been delivered intravenously, but intraembolic therapy via a pulmonary artery catheter has gained momentum. Few randomized trials have been conducted, however. Only three agents have been approved for use in the United States: streptokinase, urokinase, and tissue-type plasminogen activator. Urokinase is not currently available for use in the United States. The latter agent has been most widely used on the basis of proven benefit with a relatively short (2-hour) infusion. Newer, unapproved agents include tenecteplase and reteplase. Risk stratification in acute pulmonary embolism is important in determining which patients are the most appropriate candidates for thrombolysis, with careful consideration of contraindications.
引用
收藏
页码:452 / 458
页数:7
相关论文
共 50 条
  • [1] Thrombolytic therapy in acute pulmonary embolism
    Pilger, E
    Smolle, KH
    [J]. INTERNIST, 1996, 37 (06): : 574 - 584
  • [2] Thrombolytic therapy in acute pulmonary embolism
    Wacker, P
    Wacker, R
    [J]. HERZ, 2005, 30 (04) : 261 - 268
  • [3] Thrombolytic therapy in acute pulmonary embolism
    Tapson, Victor F.
    [J]. CURRENT OPINION IN CARDIOLOGY, 2012, 27 (06) : 585 - 591
  • [4] THROMBOLYTIC THERAPY IN ACUTE PULMONARY EMBOLISM
    HIRSH, J
    HALE, GS
    MCDONALD, IG
    [J]. ISRAEL JOURNAL OF MEDICAL SCIENCES, 1968, 4 (05): : 1098 - &
  • [5] THROMBOLYTIC THERAPY FOR ACUTE PULMONARY-EMBOLISM
    SHERMAN, BW
    RUTHERFORD, WF
    [J]. WESTERN JOURNAL OF MEDICINE, 1989, 151 (01): : 67 - 68
  • [6] THROMBOLYTIC THERAPY IN ACUTE PULMONARY-EMBOLISM
    LEVINE, MN
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 1993, 9 (02) : 158 - 159
  • [7] Thrombolytic Therapy in Octogenarians with Acute Pulmonary Embolism
    Zengin, Ahmet
    Karatas, Mehmet Baran
    Canga, Yigit
    Guzelburc, Ozge
    Yelgec, Nizamettin Selcuk
    Emre, Ayse
    [J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2022, 118 (01) : 68 - 73
  • [8] Acute Pulmonary Embolism Complicated by Thrombolytic Therapy
    Xia, Zhaofan
    Heng, Yu
    Ma, Bing
    Zhu, Shi-Hui
    Tang, Hong-Tai
    Ben, Daofeng
    [J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2010, 69 (06): : E109 - E109
  • [9] Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism
    Ibrahim, Said A.
    Stone, Roslyn A.
    Obrosky, D. Scott
    Geng, Ming
    Fine, Michael J.
    Aujesky, Drahomir
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (20) : 2183 - 2190
  • [10] THROMBOLYTIC THERAPY IN ACUTE MASSIVE PULMONARY-EMBOLISM
    MARBET, GA
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 118 (31-32) : 1138 - 1141